HomeCompareTSSNF vs GBDC

TSSNF vs GBDC: Dividend Comparison 2026

TSSNF yields 40000.00% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSSNF wins by $5.18024517379999e+22M in total portfolio value
10 years
TSSNF
TSSNF
● Live price
40000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.18024517379999e+22M
Annual income
$51,548,940,318,215,365,000,000,000,000.00
Full TSSNF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — TSSNF vs GBDC

📍 TSSNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSSNFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSSNF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSSNF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSSNF
Annual income on $10K today (after 15% tax)
$3,400,000.00/yr
After 10yr DRIP, annual income (after tax)
$43,816,599,270,483,060,000,000,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, TSSNF beats the other by $43,816,599,270,483,060,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSSNF + GBDC for your $10,000?

TSSNF: 50%GBDC: 50%
100% GBDC50/50100% TSSNF
Portfolio after 10yr
$2.590122586899995e+22M
Annual income
$25,774,470,159,107,683,000,000,000,000.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TSSNF
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSSNF buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSSNFGBDC
Forward yield40000.00%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$5.18024517379999e+22M$20.78M
Annual income after 10y$51,548,940,318,215,365,000,000,000,000.00$16,389,263.41
Total dividends collected$5.178579568047658e+22M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TSSNF vs GBDC ($10,000, DRIP)

YearTSSNF PortfolioTSSNF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$4,010,700$4,000,000.00$12,490$1,790.28+$4.00MTSSNF
2$1,503,618,552$1,499,327,102.80$16,522$3,157.73+$1503.60MTSSNF
3$526,936,342,129$525,327,470,278.19$23,578$5,898.68+$526936.32MTSSNF
4$172,618,628,820,566$172,054,806,934,488.28$37,115$11,886.75+$172618628.78MTSSNF
5$52,860,672,107,805,460$52,675,970,174,967,450.00$66,136$26,423.57+$52860672107.74MTSSNF
6$15,132,132,379,588,594,000$15,075,571,460,433,242,000.00$137,257$66,491.44+$15132132379588.46MTSSNF
7$4,049,462,878,006,525,600,000$4,033,271,496,360,366,000,000.00$341,734$194,868.54+$4049462878006525.00MTSSNF
8$1,013,053,710,099,385,500,000,000$1,008,720,784,819,918,400,000,000.00$1,050,788$685,133.02+$1013053710099385472.00MTSSNF
9$236,926,560,546,299,530,000,000,000$235,842,593,076,493,200,000,000,000.00$4,099,314$2,974,971.01+$236926560546299510784.00MTSSNF
10$51,802,451,737,999,890,000,000,000,000$51,548,940,318,215,365,000,000,000,000.00$20,775,530$16,389,263.41+$5.18024517379999e+22MTSSNF

TSSNF vs GBDC: Complete Analysis 2026

TSSNFStock

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Full TSSNF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TSSNF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSSNF vs SCHDTSSNF vs JEPITSSNF vs OTSSNF vs KOTSSNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.